OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 580 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Shorter Course of Radiation Is Effective, Safe for Some with Early-Stage... November 30, 2022 AI is impacting cancer care, but also the environment September 25, 2025 Palliative and Supportive Care for Children With Cancer: An Expert Perspective October 5, 2023 FDA Approves Polatuzumab Vedotin-piiq for Previously Untreated Diffuse Large B-Cell Lymphoma,... April 27, 2023 Load more HOT NEWS Study Shows Thymic Health is Linked to Cancer Patients’ Response to... Excellence in cancer research nursing: Celebrating innovation during tough times Mom Walks In To Comfort Scared Son After Surgery And Sees... “Glossy” Awareness Campaigns Weren’t Representing Her Cancer, So She Started #TrueCancerBodies
